文献速递慢性肾脏病

成纤维细胞生长因子23与肌肉消耗:代谢视角

Fibroblast Growth Factor 23 and Muscle Wasting: A Metabolic Point of View.
PubMed 文献 · Kidney Int Rep · 2023-05-03

本文综述了FGF23在慢性肾脏病(CKD)中对骨骼肌的代谢作用。CKD中FGF23升高且其共受体α-klotho受抑制。FGF23与CKD骨骼肌消耗的多种机制相关,包括系统性及局部炎症、氧化应激增强、胰岛素抵抗和脂肪细胞因子代谢异常。

要点

  • CKD中FGF23升高且α-klotho受抑制,与骨骼肌消耗相关。
  • FGF23与炎症、氧化应激、胰岛素抵抗及脂肪细胞因子异常相关。
  • 研究FGF23对肌肉的代谢作用可提供CKD代谢异常新见解。

核心结论

  • FGF23与CKD中骨骼肌消耗的多种机制相互关联,包括系统性及局部炎症、氧化应激增强、胰岛素抵抗和脂肪细胞因子代谢异常。

研究设计与样本

  • 综述,检索范围未在原文摘要中报告。

主要发现

  • CKD中FGF23升高且其共受体α-klotho受抑制。
  • FGF23与系统性及局部炎症、氧化应激增强、胰岛素抵抗和脂肪细胞因子代谢异常等骨骼肌消耗机制相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Protein energy wasting (PEW), mostly characterized by decreased body stores of protein and energy sources, particularly in the skeletal muscle compartment, is highly prevalent in patients with moderate to advanced chronic kidney disease (CKD). Fibroblast growth factor 23 (FGF23) is an endocrine hormone secreted from bone and has systemic actions on skeletal muscle. In CKD, FGF23 is elevated and its coreceptor α-klotho is suppressed. Multiple lines of evidence suggest that FGF23 is interconnected with various mechanisms of skeletal muscle wasting in CKD, including systemic and local inflammation, exaggerated oxidative stress, insulin resistance (IR), and abnormalities in adipocytokine metabolism. Investigation of metabolic actions of FGF23 on muscle tissue could provide new insights into metabolic and nutritional abnormalities observed in patients with CKD.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Elsurer Afsar R, Afsar B, Ikizler TA, et al. Fibroblast Growth Factor 23 and Muscle Wasting: A Metabolic Point of View. Kidney Int Rep. 2023. PMID: 37441473. doi:10.1016/j.ekir.2023.04.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。